CATEGORY

January 14, 2022

After Launching World’s First TriChroma Laser TV L9 Series, Hisense Now Brings the Series’ 100L9G to Africa

CAPE TOWN, South Africa, Jan. 14, 2022 /PRNewswire/ — Hisense, provider of high-performance televisions and appliances, has announced the world’s first 100-inch L9G TriChroma Laser TV featuring 4K UHD resolution, 107% BT 2020 Colour Gamut, and Dolby Atmos® speaker system, is now available in Africa. Following the introduction of the world’s first Dual Colour

Continue Reading

AscendEX Lists the Marvelous NFT Token, MNFT

International, Jan. 13, 2022 (GLOBE NEWSWIRE) — AscendEX is excited to announce the listing of the Marvelous NFT Token (MNFT) under the trading pair MNFT/USDT on AscendEX starting on January 14 at 5:30 p.m. UTC. Marvelous NFTs is a blockchain game development company and the official intellectual property licensee of

Continue Reading

AscendEX Lists Battle of Guardians Token, BGS

International, Jan. 13, 2022 (GLOBE NEWSWIRE) — AscendEX is thrilled to announce the listing of the Battle of Guardians Share Token (BGS) under the trading pair BGS/USDT starting on January 14th at 2 p.m. UTC. Battle of Guardians (BOG) is a real-time, multiplayer NFT fighting game that allows players to

Continue Reading

Adagio Therapeutics Divulga Resumo da Atividade Neutralizante do ADG20 Contra Variantes do SARS-CoV-2 e Descreve Iniciativas para Abordar o Omicron

Publicações recentes de vários laboratórios independentes mostram que o ADG20 tem atividade neutralizante com potência comparável a outros anticorpos que retêm atividade contra o Omicron Múltiplos Esforços em Andamento para Abordar Variantes Omicron e Potenciais Futuras de SARS-CoV-2 WALTHAM, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) — A Adagio Therapeutics, Inc.,

Continue Reading

Adagio Therapeutics résume l’activité neutralisante de l’ADG20 contre les variants du SARS-CoV-2 et décrit ses initiatives visant à contrer Omicron

Des publications récentes de plusieurs laboratoires indépendants montrent que l’ADG20 a une activité neutralisante présentant une puissance comparable à d’autres anticorps et qui reste active contre Omicron Plusieurs initiatives sont en cours pour traiter Omicron et les futurs variants potentiels du SARS-CoV-2 WALTHAM, Massachusetts, 14 janv. 2022 (GLOBE NEWSWIRE) —

Continue Reading

Recent Posts